TY - JOUR
T1 - Association of high level of hs-CRP with in-stent restenosis
T2 - A case-control study
AU - Baktashian, Mojtaba
AU - Saffar Soflaei, Sara
AU - Kosari, Negin
AU - Salehi, Mansoor
AU - Khosravi, Alireza
AU - Ahmadinejad, Maliheh
AU - Moohebati, Mohsen
AU - Ebrahimi, Mahmood
AU - Rahmani, Farzad
AU - Khameneh-Bagheri, Ramin
AU - Ahmadi, Mostafa
AU - Sadabadi, Fatemeh
AU - Tayefi, Maryam
AU - Bazhdanzadeh, Suzan
AU - Ferns, Gordon A.
AU - Hashemi, Seyed Mohammad
AU - Pasdar, Alireza
AU - Ghayour-Mobarhan, Majid
N1 - The study protocol was given approval by the Ethics Committee of Mashhad University of Medical Sciences and written informed consent was obtained from participants.
Funding Information:
This study was supported by Mashhad University of Medical Sciences . The authors would like to thank technicians of Sina, Sadi, Ghaem catheterization laboratory and technicians of Isfahan Alzahra genetics laboratory.
Publisher Copyright:
© 2018 Elsevier Inc.
PY - 2019/7
Y1 - 2019/7
N2 - Background: In-stent restenosis (ISR) is one adverse outcome of coronary stent implantation. Although using drug-eluting stents has reduced the rate of ISR, it remains a major problem. Here, we have investigated the relationship between several patient characteristics including serum high sensitive C-reactive protein (hs-CRP) and ISR. Methods: This was a case-control study comprising 104 individuals with ISR and 202 patients without. Baseline characteristics were collected using a questionnaire. Fasting blood glucose (FBG), serum triglycerides (TG), total cholesterol (TC), high density lipoprotein cholesterol (HDL-C) and serum high sensitivity C-reactive protein (hs-CRP) were measured using commercial kits on an auto-analyzer. Data were analyzed using SPSS software and a p value ≤ 0.05 was considered significant. Results: Diabetes mellitus (p < 0.001), stent type (p = 0.005), serum hs-CRP (p = 0.006), FBG (p = 0.038) and serum TG (p = 0.039) were significantly associated with ISR. The association between hs-CRP and ISR remained significant after adjustment for stent type and DM. For patients with a serum hs-CRP <2.64 mg/dL, ISR was only associated with diabetes mellitus (p = 0.016); while for individuals with a serum hs-CRP ≥2.64 mg/dL, ISR was also associated with the presence of diabetes mellitus, serum triglycerides and stent type. Conclusion: Higher levels of serum hs-CRP were significantly associated with the occurrence of ISR.
AB - Background: In-stent restenosis (ISR) is one adverse outcome of coronary stent implantation. Although using drug-eluting stents has reduced the rate of ISR, it remains a major problem. Here, we have investigated the relationship between several patient characteristics including serum high sensitive C-reactive protein (hs-CRP) and ISR. Methods: This was a case-control study comprising 104 individuals with ISR and 202 patients without. Baseline characteristics were collected using a questionnaire. Fasting blood glucose (FBG), serum triglycerides (TG), total cholesterol (TC), high density lipoprotein cholesterol (HDL-C) and serum high sensitivity C-reactive protein (hs-CRP) were measured using commercial kits on an auto-analyzer. Data were analyzed using SPSS software and a p value ≤ 0.05 was considered significant. Results: Diabetes mellitus (p < 0.001), stent type (p = 0.005), serum hs-CRP (p = 0.006), FBG (p = 0.038) and serum TG (p = 0.039) were significantly associated with ISR. The association between hs-CRP and ISR remained significant after adjustment for stent type and DM. For patients with a serum hs-CRP <2.64 mg/dL, ISR was only associated with diabetes mellitus (p = 0.016); while for individuals with a serum hs-CRP ≥2.64 mg/dL, ISR was also associated with the presence of diabetes mellitus, serum triglycerides and stent type. Conclusion: Higher levels of serum hs-CRP were significantly associated with the occurrence of ISR.
KW - Bare stent
KW - Drug-eluting stent
KW - Hs-CRP
KW - In-stent restenosis (ISR)
UR - http://www.scopus.com/inward/record.url?scp=85053297361&partnerID=8YFLogxK
U2 - 10.1016/j.carrev.2018.08.015
DO - 10.1016/j.carrev.2018.08.015
M3 - Article
C2 - 30232022
AN - SCOPUS:85053297361
VL - 20
SP - 583
EP - 587
JO - Cardiovascular revascularization medicine : including molecular interventions
JF - Cardiovascular revascularization medicine : including molecular interventions
SN - 1878-0938
IS - 7
ER -
